

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

SOLUS et al.

Appl. No.: 09/891,332

Filed: June 27, 2001

For: Polymerases for Analyzing or Typing Polymorphic Nucleic Acid Fragments and Uses Thereof Confirmation No.: 4572

Art Unit: 1637

Examiner: Tung, J.

Atty. Docket: 0942.4250003/BJD/JKM

Fourth Supplemental Information Disclosure Statement

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

Listed on accompanying PTO/SB/08B Form are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. A copy of each document is attached.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO/SB/08B Form based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

Applicants have checked the appropriate boxes below.

- ☐ 1. Statement under 37 C.F.R. 1.704(d). Each item of information contained in this
 Information Disclosure Statement was cited in a communication from a foreign
 patent office in a counterpart application and this communication was not
 received by any individual designated in 37 C.F.R. § 1.56(c) more than thirty
 days prior to the filing of this information disclosure statement.

continued examination under 37 C.F.R. § 1.114 (filed herewith). No statement or fee is required.

- 3. Filing under 37 C.F.R. § 1.97(c). This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection, or Notice of Allowance, or an action that otherwise closes prosecution in the application.
 - a. Statement under 37 C.F.R. § 1.97(e)(1). I hereby state that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1).
 - b. Statement under 37 C.F.R. § 1.97(e)(2). I hereby state that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2).

	□ c.	Attached is our PTO-2038 Credit Card Payment Form in the			
		amount of \$ in payment of the fee under 37 C.F.R. §			
		1.17(p).			
4 .	Filing under 3	37 C.F.R. § 1.97(d) This Information Disclosure Statement is being			
	filed more than three months after the U.S. filing date and after the mailing date				
	of a Final Rej	ection or Notice of Allowance, but before payment of the Issue Fee.			
	Enclosed find our PTO-2038 Credit Card Payment Form in the amount of				
	\$ in 1	payment of the fee under 37 C.F.R. § 1.17(p); in addition:			
	□ a.	Statement under 37 C.F.R. § 1.97(e)(1). I hereby state that each			
		item of information contained in this Information Disclosure			
		Statement was first cited in any communication from a foreign			
		patent office in a counterpart foreign application not more than			
		three months prior to the filing of this Information Disclosure			
		Statement. 37 C.F.R. § 1.97(e)(1).			
	☐ b.	Statement under 37 C.F.R. § 1.97(e)(2). I hereby state that no item			
		of information in this Information Disclosure Statement was cited			
		in a communication from a foreign patent office in a counterpart			
		foreign application and, to my knowledge after making reasonable			
		inquiry, was known to any individual designated in 37 C.F.R. §			
		1.56(c) more than three months prior to the filing of this			
		Information Disclosure Statement 37 C F R 8 1 97(e)(2)			

	The document(s) was/were cited in a search report by a foreign patent office in a						
	counterpart foreign application. Submission of an English language version of						
	the search report that indicates the degree of relevance found by the foreign office						
	is provided in satisfaction of the requirement for a concise explanation of						
	relevance. 1138 OG 37, 38.						
☐ 6.	A concise explanation of the relevance of the non-English language document(s)						
	appears below in accordance with 37 C.F.R. § 1.98(a)(3).						
☐ 7.	Copies of documents are submitted.						
□ 8.	Copies of the documents were cited by or submitted to the Office in an IDS that						
	complies with 37 C.F.R. § 1.98(a)-(c) in Application No, filed						
	, which is relied upon for an earlier filing date under 35 U.S.C.						
	§ 120. Thus, copies of these documents are not attached. 37 C.F.R. § 1.98(d).						
<u> </u>	It is expected that the examiner will review the prosecution and cited art in the						
	parent application no(s) in accordance with MPEP 2001.06(b),						
	and indicate in the next communication from the office that the art cited in the						
	earlier prosecution history has been reviewed in connection with the present						
	application.						

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO/SB/08B Form, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Jeffrey K. Mills Agent for Applicants Registration No. 56,413

Date: August 31, 2005

1100 New York Avenue, N.W. Washington, D.C. 20005-3934 (202) 371-2600

435329_1.DOC

PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE rwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Substitut PAP form 1449/PTO Complete if Known 09/891,332 Application Number FOURTH SUPPLEMENTAL Filing Date June 27, 2001 INFORMATION DISCLOSURE Joseph SOLUS First Named Inventor STATEMENT BY APPLICANT 1637 Art Unit (Use as many sheets as necessary) Tung, J. **Examiner Name** 0942.4250003/BJD/JKM Sheet of Attorney Docket Number

		NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published		
	NPL1	HU, G., "DNA Polymerase-Catalyzed Addition of Nontemplated Extra Nucleotides to the 3' End of a DNA Fragment," <i>DNA and Cell Biology</i> 12:763-770 (1993), Mary Ann Liebert, Inc., New Rochelle, NY.		
-	NPL2	PARKER, L.T., et al., "AmpliTaq® DNA Polymerase, FS Dye-Terminator Sequencing: Analysis of Peak Height Patterns," <i>BioTechniques 21</i> : 694-699 (1996), PJB Publications, London.		
	NPL3	SHIMA, Y., et al., "Construction and Characterization of N-Terminally Truncated DNA Polymerase from <i>Thermus thermophilus</i> ," Journal of Fermentation and Bioengineering 6:504-510 (1996), Elsevier B.V., New York.		
	NPL4	YANG, SW., et al., "Mutant Thermotoga neapolitana DNA polymerase I: altered catalytic properties for non-templated nucleotide addition and incorporation of correct nucleotides," Nucleic Acids Research 30: 4314-4320 (2002), Oxford University Press, London.		
	NPL5			
	NPL6			
	NPL7			
	NPL8			
	NPL9	·		
	NPL10			

435334_1.DOC

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.